Milestone Pharmaceuticals Inc.
- Address
- 420-1111 Dr.-Frederik-Philips Boulevard
Sponsor Overview
Specializations
Cardiac Arrhythmia
Research activity is centered on paroxysmal supraventricular tachycardia, with attention to rapid heart rhythm control in patients experiencing spontaneous episodes. The clinical focus includes treatment options for younger populations affected by episodic supraventricular tachycardia.
- Paroxysmal supraventricular tachycardia
- Acute rhythm termination
- Pediatric cardiac care
The sponsor’s trial activity reflects interest in managing symptomatic arrhythmia across pediatric age groups, including adolescents and children.
Pediatric Cardiovascular Medicine
Clinical research extends to pediatric patients with episodic cardiac rhythm disturbances, covering both early adolescents and younger children. The work addresses age-specific considerations in cardiovascular treatment for acute events.
- Adolescent cardiology
- Childhood arrhythmia
- Age-specific cardiac treatment
Interest in this area includes noninvasive approaches suited to pediatric use in urgent rhythm-related episodes.
Intranasal Therapeutics
The sponsor is involved in research on intranasal delivery for cardiovascular symptom control, with emphasis on a nasal spray formulation used during active tachycardia episodes. This therapeutic area combines drug delivery with acute cardiac intervention.
- Intranasal administration
- Nasal spray therapy
- Rapid-onset treatment
This domain highlights interest in practical treatment options for timely management of PSVT outside a hospital setting.
Emergency Symptom Management
Clinical development is directed toward treatment of sudden tachyarrhythmic events that require prompt relief of palpitations and associated symptoms. The research focus includes outpatient control of episodes that begin unpredictably and resolve with targeted intervention.
- Acute episode treatment
- Palpitations
- Outpatient arrhythmia care
These studies support therapeutic interest in managing short-duration cardiac rhythm disturbances in community-based settings.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 3, Multicenter, Placebo‑Controlled Study of Intranasal Etripamil for Rapid Ventricular Rate Control in Atrial Fibrillation (ReVeRA‑301) |  The Netherlands | Not Yet Recruiting |
| The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients with Paroxysmal Supraventricular Tachycardia |  Germany Spain The Netherlands | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 24 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases2 trials359 other sponsors
Partnered Research Centres
24 centres- Address
- Molengracht 21, 4818 CK Breda
- Address
- Meibergdreef 9, 1105 AZ Amsterdam
- Address
- Boerhaavelaan 25, 4708 AE Roosendaal
- Address
- Wesselmanlaan 25, 5707 HA Helmond
- Address
- Henri Dunantweg 2, 8934 AD Heerenveen
- Address
- Paseo De La Castellana 261, 28046 Madrid
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Milestone Pharmaceuticals Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.